RWCS RWCSmtg
1 year ago
Stay sharp in RA, PsA & SpA care. Get the latest breakthroughs + expert insights at RWCS 2026. Don’t miss 'Year in Review: Rheumatology Advances.' Register now: https://t.co/majEsY4tXK https://t.co/fgGniR1OGk
Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic agents in this setting. Pulmonologists have long used antifibrotics for ILD caused by idiopathic pulmonary fibrosis (IPF) and other conditions, but rheumatologists have limited experience with these drugs.
Dr. John Cush RheumNow
1 year ago
Metanalysis of 7 studies (1979-2023) shows RA pts on vegetarian or vegan diets achieved no improvement in disease activity or physical function, but did have a small significant improvement in pain. Insufficient Data on Fatigue. Overall, low certainty https://t.co/jeh6gN5Byg
Dr. John Cush RheumNow
1 year ago
SPRING-SIR Italian registry of systemic sclerosis: 1917 SSc pts, 56% had GI Sx, assoc w/ longer Dz duration, more severe Dz, diffuse SSc, ILD, digital ulcers, telangiectasias, & tobacco. In 211 very early SSc, 41% GI Sxs (most esophageal), w/ puffy fingers, & dyspnea. https://t.co/l2hStwavuu
The European Respiratory Society (ERS) and European Alliance of Associations for Rheumatology (EULAR) have published clinical practice guidelines for the evaluation and management of connective tissue diseases (CTD) associated interstitial lung disease (ILD) in two simultaneous publications in the European Respiratory Journal and Annals of Rheumatic Diseases.
Dr. John Cush RheumNow
1 year ago
Where are we now—and where are we going in ILD treatment?
📅 September 9 (TONIGHT!)| ⏰ 7PM EST (LIVE)
Rheumatology leaders Drs. Sindhu Johnson, Dr. Anna-Maria Hoffmann-Vold, Dr. Scott Matson, and Dr. Jack Cush will review the latest ACR & EULAR guidelines on interstitial lung https://t.co/E30AirP5WX
Dr. John Cush RheumNow
1 year ago
Obstructive sleep apnea in USA is expected to rise from 34·3% in 2020 to 46·2%, resulting in 76·6 million OSA cases by 2050. By 2050 there will be more males w/ OSA (~46 milliion) than females (30·4 million), but greater growth in females over the next 30 years. https://t.co/6YZvSusTWf
Dr. John Cush RheumNow
1 year ago
Multimorbidity predicts flares in rheumatoid arthritis
A study from Olmstead county and the Mayo Clinic shows that multimorbidity and social factors predict higher rheumatoid arthritis (RA) flares and lower remission rates.
https://t.co/yGrvDttcEq https://t.co/45LMtvsFor
Dr. John Cush RheumNow
1 year ago
September to Remember (9.5.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow. This week - unemployment, diagnosing Sjogren's and a lot of ILD.
https://t.co/dPdweMaJuN https://t.co/aExU5kV26Q
The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors.
sheila RHEUMarampa
1 year ago
Based on a survey in Japan, resolution of dry mouth was the most important symptom resolution reported by SJD pts.
The JCR CPG for SjD suggests RTX for glandular involvement while BEL for extra-glandular involvements.
#APLAR25 @RheumNow https://t.co/SsUvQIM9Eu
Aurelie Najm AurelieRheumo
1 year ago
Is it D2T RA or Clinical inertia?
Concept introduced by Dr Kaneko, Japanese Keio RA cohort, followed for 5yrs
5% patients not fitting the D2T RA definition have MDA or HDA
The drivers of persistent DA in RA:
-overestimation of treatment effectiveness
-avoidance of treatment https://t.co/0pkDaUFH4R
